It said it invested nearly RON25 million in new manufacturing equipment and upgrades to its existing equipment.
“Zentiva continued to perform in 2019 despite an unfriendly environment for local generics producers. The current context once again underlines the need to treat the production of medication as a sector of strategic importance,” Simona Cocos, general manger for Romania and Moldova.
In 2019, Zentiva’s achieved production volume was 3.8% higher than in 2018.
Exports represented 40% out of the total 2019 turnover, or RON219 million, compared with 59% in 2018, or RON252 million. Exports were mainly destined for European Union markets.
OTC products (over-the-counter medicines) accounted for 5% of total sales compared with 11% in 2018, the company said.